The study behind the long identifier
SURMOUNT-5, identified by DOI 10.1056/NEJMoa2416394, directly compared tirzepatide and semaglutide in adults with obesity. At 72 weeks, mean weight reductions were 20.2% with tirzepatide and 13.7% with semaglutide. The trial was open-label, meaning the assigned treatment was known. These figures describe the study groups, not a personal prediction, a comparison of semaglutide tablets with injections or evidence about a compounded preparation.
How the source notes work
Each description identifies a source’s role. Trial findings remain tied to the studied formulation, participants and comparison. Labels establish product-specific uses and cautions. FDA and HHS documents address separate regulatory questions. A DOI is a persistent paper identifier; the links below lead to the recorded source rather than to a search result.
STEP 1: weight change with an injection
Adults with obesity, or overweight and a related condition, without diabetes received semaglutide injection or placebo alongside lifestyle support. The average weight changes at 68 weeks belong to this design. They do not describe a tablet trial or a test of every semaglutide preparation.
DOI: 10.1056/NEJMoa2032183
STEP 4: continuation after a shared start
A common initial treatment period preceded the comparison between continued semaglutide and a switch to placebo. The later results concern people who reached that point. The study helps separate maintenance from initial weight loss, without establishing a stopping method for an individual.
DOI: 10.1001/jama.2021.3224
STEP 1 follow-up: the year after treatment
This follow-up covered a smaller group from STEP 1. Semaglutide and structured lifestyle support both ended. Weight regain was observed afterward, but the design does not isolate every possible influence on that regain or describe all forms of support after treatment.
DOI: 10.1111/dom.14725
PIONEER 1: an oral formulation in diabetes
The oral semaglutide trial compared the study formulation with placebo in adults with type 2 diabetes. Blood-sugar and weight findings answer that trial’s questions. They cannot be treated as a direct tablet-versus-injection comparison, and they do not establish results for unrelated preparations.
DOI: 10.2337/dc19-0749
How the oral formulation reaches the blood
This formulation review explains the role of SNAC, a substance that helps oral semaglutide cross into the body. Its discussion supports the distinction between a tablet’s contents and an injection’s route. It supplies no simple conversion between them.
DOI: 10.2337/cd22-0118
SURMOUNT-5: the source behind NEJMoa2416394
The direct, open-label comparison in adults with obesity reported mean weight reductions of 20.2% with tirzepatide and 13.7% with semaglutide at 72 weeks. Participants and researchers knew the assigned treatment. Those are study-group results, not predictions or evidence about prescription services.
DOI: 10.1056/NEJMoa2416394
Digestive reactions across the STEP studies
The combined analysis describes digestive reactions during semaglutide injection weight-management studies. Most were mild to moderate and temporary. Combining trial data can describe a pattern while still leaving an individual symptom unexplained; it also does not establish rates for tablets.
DOI: 10.1111/dom.14551
Personal reports about appetite and eating
These accounts include descriptions of quieter recurring thoughts about food. They are anecdotal, not clinical evidence. A collection of voluntary reports cannot establish frequency, confirm causation or represent everyone taking semaglutide. It is included to identify the source of an experience phrase, not to measure a benefit.
Body composition beyond the scale
The body-composition report describes loss of fat and lean tissue. Lean tissue is a measurement category, not a direct test of muscle strength. Its findings warrant that distinction, rather than a claim that all lost weight is fat or that a scan measures physical ability.
DOI: 10.1210/jendso/bvab048.030
Appetite pathways studied in mice and rats
Animal experiments traced neural pathways involved in semaglutide-related weight change and food intake. This is preclinical evidence: work before or apart from clinical testing in people. It can inform a biological explanation without establishing a human experience or a clinical outcome.
DOI: 10.1172/jci.insight.133429
SELECT: cardiovascular outcomes in a defined group
The study enrolled adults with established cardiovascular disease and overweight or obesity, without diabetes. It compared cardiovascular events under semaglutide injection and placebo. That population matters: a result in people with existing disease is not a general prevention claim for all adults.
DOI: 10.1056/NEJMoa2307563
Wegovy: the form-specific label
The combined label distinguishes semaglutide injection from tablets, their approved uses and product-specific evidence. It also records warnings and contraindications, meaning circumstances that rule out use. The label is a source for product facts, not a replacement for assessment of a particular person.
Ozempic injection: its own prescribing information
This source concerns semaglutide injection sold as Ozempic and its adult type 2 diabetes indications. The ingredient, brand, form and purpose are separate details. A description of this injection does not identify every medicine that has used the same brand name.
Ozempic and Rybelsus: the tablet label
The combined oral label includes both tablet names. It supports the need to identify the exact formulation, including when an older article uses a different name. A shared ingredient or familiar brand does not erase the distinction between oral and injectable evidence.
FDA: what compounding does and does not mean
FDA explains that compounded drugs are not FDA-approved and do not undergo its premarket review of safety, effectiveness and quality. This is a statement about compounded preparations, distinct from the approvals of manufactured semaglutide medicines. A prescription alone does not confer approval.
FDA concerns about unapproved GLP-1 preparations
The agency describes adverse-event reports that may be related to dosing errors with compounded injectable semaglutide, including reports requiring hospitalization. Reports identify concerns; they are not a controlled trial measuring how often an error occurs across all users.
The October 30 HHS draft concerns six other peptides
The draft, nonbinding enforcement-discretion policy addresses six named single-ingredient peptides under 503A conditions. It does not include semaglutide, blends or 503B outsourcing facilities. It neither approves a drug nor changes an FDA bulks list. Its scope cannot establish a semaglutide compounding route.